Steve Kelly

A lung cancer screening may help detect the disease before it has spread. This #LungCancerAwarenessMonth, learn how Merck’s “Focus On Your Lungs” program helps uncover fact versus fiction about this important step for those eligible for a lung cancer screening: http://merck.us/3Ak7d9u #MerckProud

21

When nearly half of the public and a third of health policymakers are unable to identify chronic obstructive pulmonary disease (COPD) as a lung disease, it’s time to Speak Up. This disease can be debilitating and impacts an est. 391M people, creating burdens on their families and health systems around the world. Action is needed. We can be the catalyst. At AstraZeneca we’re proud to be founding members of the influential campaigning coalition, Speak Up for COPD. Today alongside our partners, we’re launching The Global State of COPD Report, which provides policymakers with a solutions framework and best practices to transform care for people with COPD. We need you to #SpeakUpforCOPD and bring it to the top of policy agendas. Check out the report, share it, lend your voice, create change: https://lnkd.in/eCEQ7KM8

13

Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers: DelveInsight’s, “Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading → #PharmaceuticalsBiotech

1

At AbbVie, understanding the patient experience is at the center of everything we do. The “Gutsy IBD Conversations” series provides insight from HCPs and inspiring stories from people with IBD, like Beatriz. Watch her story: https://lnkd.in/gw5c7kKf #WorldIBDDay #WeAreAbbVie

23

1 Comment

Is it your next challenge to become a great manager? 🌟 Annie McKee's article "Shifting from Star Performer to Star Manager" offers valuable insights: • Redirect your achievement drive to empower others • Navigate the delicate balance of workplace relationships • Use your influence for the greater good Great management isn't just about results—it's about understanding and leveraging your emotional intelligence to bring out the best in your team. 🧠💪 Read the full article to learn how to evolve from a star performer to a star manager! #CareerAdvancement #LeadershipSkills #EmotionalIntelligence

3

In this edition of the New Medicines, Novel Insights newsletter, Paul Bridges chats with clinical experts from Parexel and Health Advances about the critical decision points in the pre-clinical phase that can ultimately determine the success of your product. Learn how these experts are helping biotech companies reduce risk by advocating for better coordination among departments, with a clear patient focus, at the earliest stages. Create success by planning for it ✅ Read the full article below and subscribe for our latest #NovelInsights #ParexelBiotech #ClinicalDevelopment #EarlyPhase #DrugDevelopment

8

Erin here, back again with a Real Chemistry readout of the health policy discussion few are talking about from last night’s VP debate with Leslie Isenegger, MPP.   Over an hour into the debate, Senator JD Vance and Governor Tim Walz were asked about the cost of healthcare. The back and forth mostly focused on who has done more to strengthen the Affordable Care Act (Vance seemingly countering efforts by the Trump administration to weaken the law). But Vance echoed Trump’s vow to repeal the ACA and touted pre-ACA high risk pools, which led to a sharp rebuke from Walz.     On drug pricing, it’s no surprise that Gov. Walz highlighted the Medicare Drug Price Negotiation Program as key to VP Harris’s efforts to bring down costs. Vance claimed the average increase in drug prices under the Trump administration was 1.5% compared to a 7% increase under the Biden administration.     Vance appeared to be citing a HHS report tracking drug prices from 2017-2023. He may have conflated a 7% average price increase on single source drugs from 2022-2023, which was due to price increases on higher priced drugs, with a different statistic that showed 1.6% increase in the consumer price index from 2017-2018. Interestingly, neither candidate mentioned the $35 insulin cap despite both candidates taking credit for that measure.      This debate demonstrated that both candidates would plan to make drug prices a priority of their administrations, despite reports that Congressional Republicans are targeting Medicare price negotiation as a target for repeal in 2025.   https://lnkd.in/dHssXaPe

27

1 Comment

At CancerVAX, we're thrilled to announce a major step forward in our fight against Ewing sarcoma, a devastating childhood cancer. For nearly three years, we've been working alongside a world-class team of researchers at UCLA.  Their passion and dedication have resulted in a promising new weapon: a "bio-specific antibody vaccine" designed specifically to target Ewing sarcoma. This innovative vaccine trains the body's own immune system to recognize and destroy cancer cells. Early lab studies have shown encouraging results, prompting us to file an IND application with the FDA for approval to begin human trials. This is a pivotal moment for CancerVAX.  If successful, this vaccine could not only revolutionize the treatment of Ewing sarcoma but also pave the way for a more comprehensive, universal cancer vaccine. We're incredibly excited about the potential impact of this research and can't wait to share updates on the progress of human trials.  Stay tuned for more news! #EwingSarcoma #CancerResearch #Immunotherapy #Breakthrough #HopeForACure #Cancer #Hope  #FYP #Explore 

7

1 Comment

As a rare disease patient, post-trial access as a topic is close to my heart because we often have very limited treatment options. Losing access to a treatment which has been benefitting us as part of clinical trial could even be life threatening. I am proud of the fact that I am part of an organization that is among the first companies to guarantee continued access - called post-trial access - for participants of any clinical trial from the time each patient finishes the trial. If the results show superior efficacy, access is continued until the drug is on the market and reimbursed (where applicable). PS: When a clinical trial ends, it takes months or even years before a drug reaches the market. #inspired #curious #unbossed #access #novartis Paul Aliu Marion Dahlke Michael Steel Goran Mijuk Elizabeth Adamson Marjolein Willemen Neelesh Dongre Hanna Rueggeberg

60

2 Comments

The trajectory of the mRNA modality is set to keep rising. Post-COVID-19 and the deployment of mRNA vaccines against the infectious disease, biopharma, and academic and industry groups have programs to expand mRNA use to other human diseases. Want to learn more about the mRNA modality? Access a free, three-module course from Moderna via Coursera. No science background is required. The course offers a comprehensive understanding of mRNA medicines, how they work, and their potential applications. For $APDN investors, you will gain insight into the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases that LineaRx, Inc., our biotherapeutics subsidiary, can enable. Applied DNA Sciences #mRNA #geneticmedicine

4

Here's an honest confession. I love listening to town hall recordings over and over again. Because sometimes when you only watch once, it's most likely that you'll miss a golden nugget. Like this one from Shreeram Aradhye during our recent Development Live Connect at Novartis - "Be proud of your portrait identities but work in landscape mode. That's where magic happens - turning molecules into medicines for our patients." What a profound metaphor! Our 'portrait mode' represents our deep specialty expertise, years of focused experience in our domains. But the landscape? That's where these specialized skills converge as part of a team to create breakthrough solutions. Think about it - while our individual portraits of expertise are crucial, innovation truly accelerates in 'landscape mode' - where different specialties collaborate as part of a team, where diverse perspectives converge, and where expertise crosses boundaries. Thank you, Shreeram, for this powerful reminder that while our deep specialties make us experts, our ability to work in the landscape mode makes us truly transformative. #innovation #leadership #healthcare #collaboration #townhall #teamwork Maria Bellostas Baeza Michael Billings

250

5 Comments

This article struck a chord with me. It’s about moving purposely toward a long-term vision in a world where we’ve come to place more value on agility and being able to pivot quickly.   The tension between doing things fast and doing things well came to mind. To be clear – they aren’t always mutually exclusive. We’re side-by-side with our clients and the round-the-clock expectations and urgency they deal with every day. Business happens at speed and acting quickly is often a necessity. But there are times when “fast” can work against us.   More intellectual work – like foundational messaging, like deep thought leadership – requires time to ponder, analyze, self-critique, go away and return with fresher eyes and sharper minds. When you cut that out, the result is like fast-fashion – it looks passable on the surface, but it doesn’t hold up to scrutiny and doesn’t hold lasting value.   It’s always about striking a happy balance.   Definitely worth a read. #Healthcare #Messaging #BuiltToLast

14

4 Comments